1.中国抗癌协会肿瘤病理专业委员会分子病理协作组, 中国医师协会肿瘤多学科诊疗专业委员会. 非小细胞肺癌表皮生长因子受体20号外显子插入突变检测临床实践中国专家共识(2024版)[J]. 中华肿瘤杂志,2024,46(3):179-188.
11.SHI Y, ZHOU J, ZHAO Y, et al. 981P A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naïve NSCLC patients with EGFR mutation[J]. ANNALS OF ONCOLOGY, 2022,33:S1000.
14.YU J, ZHOU C, KAI W, et al. Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8546-8546.
17.Y. ZHANG L Z, N. YANG W J, Y. XIONG Z W, et al. 667P - Furmonertinib 160mg as first-line treatment for metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases[J]. ANNALS OF ONCOLOGY, 2024,35(suppl_4):S1632-S1678.
18.M. SHI B S, C. WANG L Z, Y. ZHU L W, et al. 658P - Furmonertinib 160mg as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 21 L858R mutation[J]. ANNALS OF ONCOLOGY, 2024,35(suppl_4):S1632-S1678.
19.FAN Y, LI H, XU Y, et al. High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):2007-2007.
20.CHO B C, FELIP E, SPIRA A I, et al. LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial[J]. ANNALS OF ONCOLOGY, 2023,34:S1306.
22.FELIP E, CHO B C, GUTIéRREZ V, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8504-8504.
23.GADGEEL S, CHO B C, LU S, et al. OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study[J]. Abstracts from the 2024 World Conference on Lung Cancer, 2024,19(10, Supplement):S10-S11.
24.NGUYEN D, BESSE B, CHO B C, et al. MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA[J]. Abstracts from the 2024 World Conference on Lung Cancer, 2024,19(10, Supplement):S103-S104.
25.LIM S M, TAN J, MOURãO DIAS J, et al. Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(17_suppl):LBA8612-LBA8612.
26.ZHANG L, FANG W F, ZHAO S, et al. 614MO A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)[J]. ANNALS OF ONCOLOGY, 2024,35:S1624-S1625.
27.JANNE P, PLANCHARD D, CHENG Y, et al. PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)[J]. Abstracts from the 2023 World Conference on Lung Cancer, 2023,18(11, Supplement):S36-S37.
29.VALDIVIEZO N, OKAMOTO I, HUGHES B G M, et al. 4O First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes[J]. ESMO Open, 2024,9
30.LEE C K, CHENG Y, LAKTIONOV K, et al. 9P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs)[J]. ESMO Open, 2024,9
31.LEE C K, PLANCHARD D, FAN Y, et al. 10P Safety and tolerability of first-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: Data from FLAURA2[J]. ESMO Open, 2024,9
32.HAN B, CHU T, YU G, et al. 15P Furmonertinib combined with anlotinib as the first-line treatment in patients with EGFR exon 21 Leu858Arg mutation: Results from FOCUS-A study[J]. ESMO Open, 2024,9
33.CHEN H L, CHEN R, XIA T, et al. 697P Aumolertinib plus anlotinib as first-line treatment for EGFR mutant non-small cell lung cancer: A phase II trial (ALWAYS)[J]. ANNALS OF ONCOLOGY, 2024,35:S1665.
[34 HAN B, YAN B, CHU T, et al. 649P An oral, chemo-free regimen (osimertinib plus anlotinib) as first-line treatment for EGFR-mutated advanced NSCLC (AUTOMAN): Safety and survival outcome[J]. ANNALS OF ONCOLOGY, 2024,35:S1647.
34.YOH K, KATO T, NAKAHARA Y, et al. OSIRAM-1/TORG1833: Overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8613-8613.
35.LE X, PATEL J D, SHUM E, et al. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,0(0):JCO.24.00533.
36.ZHAO S, ZHAO H, ZHANG L, et al. Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC)[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8077-8077.
37.LE X, ELAMIN Y Y, ALTAN M, et al. 16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer[J]. ESMO Open, 2024,9
38.CHEN H, HUANG G, XIA T, et al. P3.12D.05 Furmonertinib Plus Icotinib as First-Line Treatment in EGFR-Mutated NSCLC: Updated Results in L858R and CNS Metastases Groups[J]. Journal of Thoracic Oncology, 2024,19(10):S348.
39.YANG J, LI A, FENG W N, et al. PL04.10 Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial[J]. Journal of Thoracic Oncology, 2024,19(10):S6.
40.李咏生, 孙建国, 李梦侠,等. 第三代EGFR-TKI耐药后诊疗策略专家共识[J]. 中华肺部疾病杂志(电子版),2023,16(2):145-155.
41.PASSARO A, CHO B C, WANG Y, et al. LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial[J]. ANNALS OF ONCOLOGY, 2023,34:S1307.
43.GENTZLER R D, SPIRA A, MELOSKY B, et al. 3MO Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2[J]. ESMO Open, 2024,9
44.TOMASINI P, BLASCO CORDELLAT A, DOOMS C, et al. 8P Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: Secondary analyses of patient-relevant endpoints from MARIPOSA-2[J]. ESMO Open, 2024,9
45.POPAT S, RECKAMP K L, CALIFANO R, et al. LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2[J]. ANNALS OF ONCOLOGY, 2024,35:S1244-S1245.
46.YU H A, CHEN M F, HUI A B, et al. A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8517-8517.
47.LEIGHL N B, AKAMATSU H, LIM S M, et al. Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(17_suppl):LBA8505-LBA8505.
48.LEE S, AKAMATSU H, YANG J C, et al. 628MO Comparing subcutaneous vs intravenous amivantamab with lazertinib in EGFR-mutated advanced NSCLC: Analysis of Asian patients from PALOMA-3[J]. ANNALS OF ONCOLOGY, 2024,35:S1634.
49.ALEXANDER M, CHENG Y, LEE S - H, et al. OA09.05 Subcutaneous vs Intravenous Amivantamab: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study[J]. Abstracts from the 2024 World Conference on Lung Cancer, 2024,19(10, Supplement):S29.
51.ZHOU C, DONG X, CHEN G, et al. OA09.06 IMpower151: Phase III Study of Atezolizumab + Bevacizumab + Chemotherapy in 1L Metastatic Nonsquamous NSCLC[J]. Journal of Thoracic Oncology, 2023
55.PARK S, KIM T M, HAN J Y, et al. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)[J]. J Clin Oncol, 2024,42(11):1241-1251.
56.FRUEH M, SOO R A, VERVITA A, et al. 12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial[J]. ESMO Open, 2024,9
57.HAN B, ZHONG H, GUO Q, et al. 13P Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy[J]. ESMO Open, 2024,9
58.ZHANG L, FANG W, ZHAO Y, et al. Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8508-8508.
59.ZHANG L, FANG W F, ZHAO Y, et al. 134P Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)[J]. Immuno-Oncology and Technology, 2024,24
60.WU C, LV D, CUI J, et al. A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8533-8533.
61.WU Y, WANG Z, CHENG Y, et al. 1255MO A phase II safety and efficacy study of PM8002/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)[J]. ANNALS OF ONCOLOGY, 2024,35:S804.
64.GIRARD N, OKAMOTO I, LISBERG A E, et al. 59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial[J]. ESMO Open, 2024,9
65.SANDS J, LISBERG A, OKAMOTO I, et al. OA08.03 Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01[J]. Abstracts from the 2024 World Conference on Lung Cancer, 2024,19(10, Supplement):S24.
66.GARASSINO M C, SANDS J, PAZ-ARES L, et al. PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01[J]. Abstracts from the 2024 World Conference on Lung Cancer, 2024,19(10, Supplement):S2-S3.
67.LISBERG A, AHN M, KITAZONO S, et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8593-8593.
68.AHN M, SANDS J, LISBERG A E, et al. LBA7 Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05[J]. ANNALS OF ONCOLOGY, 2024,35:S1630-S1631.
69.FANG W, CHENG Y, CHEN Z, et al. Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study[J]. Cancer Res, 2024,84(7_Supplement):CT247-CT247.
70.WANG J, WU L, SONG Z, et al. 1310P SHR-A1921: A trophoblast cell-surface antigen 2 (TROP-2) targeted antibody-drug conjugate (ADC) for the treatment of advanced NSCLC[J]. ANNALS OF ONCOLOGY, 2024,35:S833.
71.YANG J C, CHEN Y, BATRA U, et al. Abstract CT251: Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi[J]. Cancer Res, 2024,84(7_Supplement):CT251-CT251.
72.MAO Y, HUANG Z, CAI D, et al. EP.12A.42 Savolitinib Plus Osimertinib in EGFR-Mutant NSCLC with MET Overexpression and Acquired Resistance to Previous EGFR Inhibitor[J]. Abstracts from the 2024 World Conference on Lung Cancer, 2024,19(10, Supplement):S638.
76.GIRARD N, PARK K, TANG K, et al. LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study[J]. ANNALS OF ONCOLOGY, 2023,34:S1304.
78.FELIP E, SHU C A, AGUILAR A, et al. 2MO Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON[J]. ESMO Open, 2024,9
79.PAZ-ARES L, VEILLON R, MAJEM M, et al. 7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC[J]. ESMO Open, 2024,9
80.TANG K, LIU B, YAO Y, et al. Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8606-8606.
81.GOLDMAN J W, CHO B C, CHENG S, et al. MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC[J]. Abstracts from the 2024 World Conference on Lung Cancer, 2024,19(10, Supplement):S102-S103.
82.LU S, ZHOU C, CHO B C, et al. 635P Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC[J]. ANNALS OF ONCOLOGY, 2024,35:S1638-S1639.
83.CHOUAID C, BOSQUET L, KNOTT C, et al. 656P Real-World (RW) frontline (1L) treatments (Txs) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EFGR) exon 20 insertions (exon20ins) and adjusted comparisons versus PAPILLON study[J]. ANNALS OF ONCOLOGY, 2024,35:S1650.
84.ZHANG L, FANG W, ZHAO S, et al. 137MO Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study)[J]. ESMO Open, 2024,9
85.JäNNE P A, WANG B, CHO B C, et al. 507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC[J]. ANNALS OF ONCOLOGY, 2023,34:S1663-S1664.
86.YANG J C, DOUCET L, WANG M, et al. A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8513-8513.
87.DOUCET L, GREILLIER L, PLANCHARD D, et al. 1260P Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study[J]. ANNALS OF ONCOLOGY, 2024,35:S807-S808.
88.PASSARO A, YU H A, NGUYEN D, et al. 1254MO Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab[J]. ANNALS OF ONCOLOGY, 2024,35:S803-S804.
89.WANG M, FAN Y, SUN M, et al. Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023,41(16_suppl):9002-9002.
90.XU Y, YANG J C, CHIU C, et al. Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023,41(16_suppl):9073-9073.
91.CHO B C, WANG Y, FELIP E, et al. Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8516-8516.
92.SATO Y, MIURA S, MISUMI T, et al. Survival outcomes and subgroup analyses derived from a phase III randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834)[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024,42(16_suppl):8588-8588.
93.LE X, YU Y, ZHAO Y, et al. PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations[J]. Journal of Thoracic Oncology, 2024,19(10):S5-S6.